130 related articles for article (PubMed ID: 25776440)
1. F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study.
Edupuganti SR; Eder V; Ternant D; Courtehoux M; Tranquart F; Goupille P; Paintaud G; Mulleman D
Joint Bone Spine; 2015 Oct; 82(5):381-3. PubMed ID: 25776440
[No Abstract] [Full Text] [Related]
2. (18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis.
Sarma M; Vijayant V; Basu S
Hell J Nucl Med; 2012; 15(1):70-1. PubMed ID: 22413120
[No Abstract] [Full Text] [Related]
3. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
Bissonnette R; Tardif JC; Harel F; Pressacco J; Bolduc C; Guertin MC
Circ Cardiovasc Imaging; 2013 Jan; 6(1):83-90. PubMed ID: 23204039
[TBL] [Abstract][Full Text] [Related]
4. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
5. (18) F-FDG PET imaging of rheumatoid articular and extraarticular synovitis.
Fonseca A; Wagner J; Yamaga LI; Osawa A; da Cunha ML; Scheinberg M
J Clin Rheumatol; 2008 Oct; 14(5):307. PubMed ID: 18838912
[No Abstract] [Full Text] [Related]
6. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in rheumatoid arthritis patients tapering tumour necrosis factor inhibitor.
Rosato E
Rheumatology (Oxford); 2022 Apr; 61(SI):SI1-SI3. PubMed ID: 34919664
[No Abstract] [Full Text] [Related]
7. Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.
Nguyen DX; Cotton A; Attipoe L; Ciurtin C; Doré CJ; Ehrenstein MR
J Allergy Clin Immunol; 2018 Sep; 142(3):978-980.e9. PubMed ID: 29935955
[No Abstract] [Full Text] [Related]
8. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
Krintel SB; Dehlendorff C; Hetland ML; Hørslev-Petersen K; Andersen KK; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard HM; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Jørgensen A; Raun J; Ammitzbøll CG; Østergaard M; Stengaard-Pedersen K; Johansen JS
Pharmacogenomics J; 2016 Apr; 16(2):141-6. PubMed ID: 25939484
[TBL] [Abstract][Full Text] [Related]
9. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT.
Okamura K; Yonemoto Y; Arisaka Y; Takeuchi K; Kobayashi T; Oriuchi N; Tsushima Y; Takagishi K
Rheumatology (Oxford); 2012 Aug; 51(8):1484-91. PubMed ID: 22513145
[TBL] [Abstract][Full Text] [Related]
10. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
Lieberman MR; Liebman TN; Alapati U; Khachemoune A
Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756476
[TBL] [Abstract][Full Text] [Related]
11. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
[TBL] [Abstract][Full Text] [Related]
12. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
13. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis.
Wakefield RJ; Freeston JE; Hensor EM; Bryer D; Quinn MA; Emery P
Arthritis Rheum; 2007 Dec; 57(8):1564-7. PubMed ID: 18050231
[No Abstract] [Full Text] [Related]
14. Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT.
Ward J; Noy A; Ulaner G; Riedl C
Clin Nucl Med; 2018 May; 43(5):344-345. PubMed ID: 29538028
[TBL] [Abstract][Full Text] [Related]
15. [A patient with rheumatoid arthritis and primary biliary cirrhosis successfully treated with adalimumab].
Bakula M; Mayer M; Čikeš N; Anić B
Lijec Vjesn; 2015; 137(1-2):27-9. PubMed ID: 25906545
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour necrosis factor α-induced lupus erythematosus panniculitis.
Durand AL; Goussot JF; Thiolat D; Taieb A; Marie J; Seneschal J; Darrigade AS
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):e318-e319. PubMed ID: 28045205
[No Abstract] [Full Text] [Related]
18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
19. Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?
Bukhari M
Rheumatology (Oxford); 2016 Sep; 55(9):1531-3. PubMed ID: 26935649
[No Abstract] [Full Text] [Related]
20. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
